| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
THDOC targets GABAA receptors, acting as a positive allosteric modulator. It potentiates GABAA receptor currents, with greatest effects at the α1β3δ isoform. The neurosteroid binds to discrete sites in the receptor's transmembrane domains. THDOC also potentiates synaptic GABAA receptor function and activates δ-subunit-containing receptors. |
|---|---|
| ln Vitro |
At healthy doses, the endogenous neurosteroid Tetrahydrodeoxycorticosterone (THDOC) preferentially increases tonic currents mediated by αβδ receptors[1]. By increasing tonic αβδ receptor currents, 10 nM tetrahydrodeoxycorticosterone decreases neuronal excitability in the hippocampal region. While 10 nM tetrahydrodeoxycorticosterone does not increase tonic currents in thalamocortical neurons, 100 nM tetrahydrodeoxycorticosterone did[1].
In cell-free systems, THDOC potentiates submaximal GABAA receptor currents. The compound enhances GABA-induced chloride currents in a concentration-dependent manner. Binding studies have identified two discrete binding sites in the GABAA receptor's transmembrane domains. THDOC shows differential effects on cerebellar and cortical GABAA receptor binding and function. Cellular electrophysiology studies demonstrate that THDOC potentiates GABAA receptor currents. Whole-cell GABA concentration-response curves show potentiation at low concentrations (30 nM). The greatest potentiation is observed for the α1β3δ isoform. THDOC potentiates synaptic GABAA receptor function and activates δ-subunit-containing receptors. |
| ln Vivo |
Tetrahydrodeoxycorticosterone (THDOC) concentrations in brain tissue from mice suffering from toxic liver injury-induced hepatic encephalopathy (HE) are high enough to cause drowsiness in other members of the same species[2].
In vivo, THDOC is an endogenous neurosteroid that modulates GABAergic neurotransmission. It is synthesized in the brain during stress, pregnancy, and after ethanol consumption. The compound modulates mood and cognitive functions through GABAA receptor modulation. THDOC has been studied for its role in stress responses and neuropsychiatric disorders. |
| Enzyme Assay |
Cellular electrophysiology experiments for THDOC are conducted using patch-clamp recordings from cells expressing recombinant GABAA receptors or native neurons. Whole-cell GABA concentration-response curves are performed with and without THDOC. The compound's positive modulatory effects are assessed by measuring potentiation of GABA-induced currents.
|
| Cell Assay |
In vivo studies on THDOC focus on its role as an endogenous neurosteroid. Animal models of stress, pregnancy, and ethanol exposure are used to study THDOC function. The compound's effects on mood and cognition are assessed using behavioral tests. THDOC levels are measured in brain tissue using analytical methods.
|
| ADME/Pharmacokinetics |
As an endogenous neurosteroid, THDOC is synthesized in the brain and metabolized through steroidogenic pathways. Its levels fluctuate in response to physiological stimuli such as stress, pregnancy, and ethanol consumption. The compound has a short half-life in the circulation due to rapid metabolism.
|
| Toxicity/Toxicokinetics |
THDOC is an endogenous compound and toxicity data are not applicable in the same sense as for xenobiotics. However, dysregulation of neurosteroid levels has been implicated in neuropsychiatric disorders. The compound's modulatory effects on GABAA receptors are generally physiological and homeostatic.
|
| References |
|
| Additional Infomation |
Tetrahydrodeoxycorticosterone is a (3α,5β) isomer.
THDOC is an important endogenous neurosteroid that modulates GABAA receptor function. It plays a role in stress responses, pregnancy, and ethanol effects. The compound is used as a research tool to study neurosteroid modulation of GABAA receptors. Its effects on mood and cognitive functions are of significant research interest. |
| Molecular Formula |
C21H34O3
|
|---|---|
| Molecular Weight |
334.49
|
| Exact Mass |
334.251
|
| CAS # |
567-03-3
|
| Related CAS # |
Tetrahydrodeoxycorticosterone-d3;72205-58-4
|
| PubChem CID |
9974162
|
| Appearance |
White to off-white solid powder
|
| Density |
1.115g/cm3
|
| Boiling Point |
470.3ºC at 760mmHg
|
| Flash Point |
252.3ºC
|
| Index of Refraction |
1.54
|
| LogP |
3.567
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O
|
| InChi Key |
CYKYBWRSLLXBOW-DATPGIFZSA-N
|
| InChi Code |
InChI=1S/C21H34O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h13-18,22-23H,3-12H2,1-2H3/t13-,14-,15+,16+,17+,18-,20+,21+/m1/s1
|
| Chemical Name |
2-hydroxy-1-[(3R,5R,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (298.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9896 mL | 14.9481 mL | 29.8963 mL | |
| 5 mM | 0.5979 mL | 2.9896 mL | 5.9793 mL | |
| 10 mM | 0.2990 mL | 1.4948 mL | 2.9896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
